We found that the combined treatment of ZCCHC4-siRNA plus OXA exhibited the most significant antitumor effects, accompanied with the most significantly reduced tumor growth, compared with in vivo administration of siRNA targeting ZCCHC4 alone or OXA alone (Fig. 3e, f and Supplementary Fig. S7d). The gene discussed is ZCCHC4; the disease is neoplasm.